Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.88 |
| ▸ | ROS1 | P08922 | 2/20 | 0.88 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.88 |
| ▸ | INSR | P06213 | 13/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | BUB1B | O60566 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | NPM1 | P06748 | 1/20 | 0.59 |
| ▸ | FES | P07332 | 1/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29562847 | 1.00 | ALK (0.88) | ALKROS1PTK2INSRKCNH2 | |
| Apg-2449 SCHEMBL21050580 | 0.94 | ALK (1.00) | ALKROS1PTK2INSRKCNH2 | |
| Apg-2449 SCHEMBL29562468 | 0.94 | ALK (1.00) | ALKROS1PTK2INSRKCNH2 | |
| Apg-2449 SCHEMBL29478899 | 0.94 | ALK (1.00) | ALKROS1PTK2INSRKCNH2 | |
| SCHEMBL22566697 | 0.88 | ALK (0.69) | ALKROS1PTK2MET | |
| SCHEMBL25222241 | 0.84 | ALK (0.83) | ALKROS1PTK2INSRKCNH2 | |
| SCHEMBL21050512 | 0.84 | ALK (0.65) | ALKROS1PTK2INSRKCNH2 | |
| SCHEMBL21050550 | 0.84 | ALK (0.65) | ALKROS1PTK2INSRKCNH2 | |
| SCHEMBL21050546 | 0.84 | ALK (0.65) | ALKROS1PTK2INSRKCNH2 | |
| SCHEMBL21050528 | 0.84 | ALK (0.65) | ALKROS1PTK2INSRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011376-B1 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2025-04-30 | — | — | EP | claimed |
| US-20230381176-A1 | A PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR TREATMENT OF CANCER | ASCENTAGE PHARMA (SUZHOU) CO., LTD (CN) | 2023-11-30 | — | — | US | claimed |
| EP-3494143-B1 | PLAZOMICIN ANTIBODIES AND METHODS OF USE | CIPLA USA INC (US) | 2022-10-05 | — | — | EP | claimed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | claimed |
| US-20210330669-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROSI INHIBITOR AND EGFR INHIBITOR | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-10-28 | — | — | US | claimed |
| US-11110090-B2 | Aminopyrimidines as ALK inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | claimed |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-14 | — | — | US | claimed |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-06-13 | — | — | US | claimed |
| EP-4011376-B1 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20230381176-A1 | A PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR TREATMENT OF CANCER | ASCENTAGE PHARMA (SUZHOU) CO., LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381176-A1 | A PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR TREATMENT OF CANCER | ASCENTAGE PHARMA (SUZHOU) CO., LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381176-A1 | A PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR TREATMENT OF CANCER | ASCENTAGE PHARMA (SUZHOU) CO., LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-4001273-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20200330464-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200330464-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-10-22 | — | — | US | disclosed |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330669-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROSI INHIBITOR AND EGFR INHIBITOR | ROS1, ALK, PTK2 | ALK 2/4885ROS1 1/4885PTK2 3/4885 |
| US-20200330464-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | ALK, RET, BRAF | ALK 1/4885ROS1 42/4885PTK2 2350/4885 |
| US-11110090-B2 | Aminopyrimidines as ALK inhibitors | ALK, RET, BRAF | ALK 1/4885ROS1 42/4885PTK2 2350/4885 |
| US-20230381176-A1 | A PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR TREATMENT OF CANCER | ALK, KIT, BRAF | ALK 1/4885ROS1 122/4885PTK2 104/4885 |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | ALK, RET, BRAF | ALK 1/4885ROS1 42/4885PTK2 2350/4885 |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | ALK, RET, BRAF | ALK 1/4885ROS1 42/4885PTK2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.